Natriuretic peptide receptor A as a novel anticancer target

Cancer Research

Volumn 68, Issue 1, 2008, Pages 249-256

  Kong, Xiaoyuan ^a   Wang, Xiaoqin ^a,d   Xu, Weidong ^a,c   Behera, Sumita ^c   Hellermann, Gary ^a   Kumar, Arun ^a   Lockey, Richard F ^a,b   Mohapatra, Subhra ^a,b   Mohapatra, Shyam S ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TransGenex Nanobiotech Inc   (United States)

^d MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOPARTICLE; NATRIURETIC PEPTIDE RECEPTOR A; NP 73102; RETINOBLASTOMA PROTEIN; RNA; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; GUANYLATE CYCLASE; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG METASTASIS; MELANOMA B16; MOUSE; NONHUMAN; OVARY CANCER; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CANCER; TUMOR CELL; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; CELL TRANSFORMATION; DRUG ANTAGONISM; GENETICS; INFLAMMATION; LUNG TUMOR; METABOLISM; MOUSE MUTANT; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SKIN TUMOR; VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GUANYLATE CYCLASE; INFLAMMATION; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; OVARIAN NEOPLASMS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39149090014     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3086     Document Type: Article

References (44)

1. Vesely DL. Atrial natriuretic hormones originating from the N-terminus of the atrial natriuretic factor prohormone. Clin Exp Pharmacol Physiol 1995;22:108-14.
2. Vesely DL. Atrial natriuretic peptides in pathophysiological diseases. Cardiovasc Res 2001;51:647-58.
3. Vesely DL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-9.
4. Vesely DL, Chiou S, Douglass MA, McCormick MT, Rodriguez-Paz G, Schocken DD. Atrial natriuretic peptides negatively and positively modulate circulating endothelin in humans. Metabolism 1996;45:315-9.
5. Vesely DL, Perez-Lamboy GI, Schocken DD. Vessel dilator, long acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2. Life Sci 2000;66:905-13.
6. Vesely DL, Perez-Lamboy GI, Schocken DD. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of β2-microglobulin. Metabolism 2000;49:1592-7.
7. Vesely DL, San Miguel GI, Hassan I, Schocken DD. Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of CRH, corticotropin, and cortisol. J Clin Endocrinol Metab 2001;86:4244-9.
8. Vesely DL, San Miguel GI, Hassan I, Schocken DD. Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations. Horm Metab Res 2002;34:245-9.
9. Fiscus RR. Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells. Neurosignals 2002;11:175-90.
10. Pedram A, Razandi M, Kehrl J, Levin ER. Natriuretic peptides inhibit G protein activation. Mediation through cross-talk between cyclic GMP-dependent protein kinase and regulators of G protein-signaling proteins. J Biol Chem 2000;275:7365-72.
11. Silberbach M, Roberts CT, Jr. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal 2001;13:221-31.
12. Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V, Milevoj-Ribic F. Cytokines in patients with lung cancer. Scand J Immunol 2003;57:173-8.
13. Martin J, Quiroga JA, Navas S, Pardo M, Carreno V. Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine 1999;11:267-73.
14. Bliss DP, Jr., Battey JF, Linnoila RI, Birrer MJ, Gazdar AF, Johnson BE. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst 1990;82:305-10.
15. Ohsaki Y, Gross AJ, Le PT, Oie H, Johnson BE. Human small cell lung cancer cells produce brain natriuretic peptide. Oncology 1999;56:155-9.
16. Ohsaki Y, Yang HK, Le PT, Jensen RT, Johnson BE. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res 1993;53:3165-71.
17. Izumi T, Saito Y, Kishimoto I, et al. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-κB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 2001;108:203-13.
18. Tunny TJ, Jonsson JR, Klemm SA, Ballantine DM, Stowasser M, Gordon RD. Association of restriction fragment length polymorphism at the atrial natriuretic peptide gene locus with aldosterone responsiveness to angiotensin in aldosterone-producing adenoma. Biochem Biophys Res Commun 1994;204:1312-7.
19. Vesely DL. Atrial natriuretic peptides: anticancer agents. J Investig Med 2005;53:360-5.
20. Hellermann G, Kong X, Gunnarsdottir J, et al. Mechanism of bronch oprotective effects of a novel natriuretic hormone peptide. J Allergy Clin Immunol 2004;113:79-85.
21. Mohapatra SS, Lockey RF, Vesely DL, Gower WR, Jr. Natriuretic peptides and genesis of asthma: an emerging paradigm? J Allergy Clin Immunol 2004;114:520-6.
22. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis 2007;28:507-18.
23. Martey CA, Pollock SJ, Turner CK, et al. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 2004;287:L981-91.
24. Knaapen AM, Borm PJ, Albrecht C, Schins RP. Inhaled particles and lung cancer. Part A: Mechanisms. Int J Cancer 2004;109:799-809.
25. Arenberg D. Chemokines in the biology of lung cancer. J Thorac Oncol 2006;1:287-8.
26. Pandey KN, Nguyen HT, Sharma GD, Shi SJ, Kriegel AM. Ligand-regulated internalization, trafficking, and down-regulation of guanylyl cyclase/atrial natriuretic peptide receptor-A in human embryonic kidney 293 cells. J Biol Chem 2002;277:4618-27.
27. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 2006;26:4143-8.
28. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells. Anticancer Res 2006;26:3217-22.
29. Karin M. Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann Rheum Dis 2004;63 Suppl 2:ii62-4.
30. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
31. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
32. Massion PP, Carbone DP. The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respir Res 2003;4:12.
33. Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNF-α-induced apoptosis through the downregulation of NF-κB-dependent antiapoptotic gene products: role of IκBα kinase and TGF-β-activated kinase-1. J Immunol 2007;178:2507-16.
34. Ashworth T, Roy AL. Cutting edge: TFII-I controls B cell proliferation via regulating NF-κB. J Immunol 2007;178:2631-5.
35. Inoue J, Gohda J, Akiyama T, Semba K. NF-κB activation in development and progression of cancer. Cancer Sci 2007;98:268-74.
36. Kim S, Millet I, Kim HS, et al. NF-κ B prevents β cell death and autoimmune diabetes in NOD mice. Proc Natl Acad Sci U S A 2007;104:1913-8.
37. Oka D, Nishimura K, Shiba M, et al. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-κB. Int J Cancer 2007;120:2576-81.
38. Saccani A, Schioppa T, Porta C, et al. p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006;66:11432-40.
39. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007;13:70-7.
40. Schmidt D, Textor B, Pein OT, et al. Critical role for NF-κB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J 2007;26:710-9.
41. Vellaichamy E, Sommana NK, Pandey KN. Reduced cGMP signaling activates NF-κB in hypertrophied hearts of mice lacking natriuretic peptide receptor-A. Biochem Biophys Res Commun 2005;327:106-11.
42. Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 2005;124 Suppl:S16-28.
43. Gabellini C, Del Bufalo D, Zupi G. Involvement of RB gene family in tumor angiogenesis. Oncogene 2006;25:5326-32.
44. Fluge T, Forssmann WG, Kunkel G, et al. Bronchodilation using combined urodilatin - albuterol administration in asthma: a randomized, double-blind, placebo-controlled trial. Eur J Med Res 1999;4:411-5.